Jiangsu Kanion PharmaceuticalLtd 관리

관리 기준 확인 4/4

Jiangsu Kanion PharmaceuticalLtd CEO는 Yongchun Yang, Apr2021 에 임명되었습니다 의 임기는 3.58 년입니다. 는 CN¥ 3.00M 가치에 해당하는 회사 주식의 0.037% 직접 소유합니다. 3.00M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 3.5 년입니다.

주요 정보

Yongchun Yang

최고 경영자

CN¥758.6k

총 보상

CEO 급여 비율	n/a
CEO 임기	3.6yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

CEO

Yongchun Yang (51 yo)

3.6yrs

테뉴어

CN¥758,600

보상

Mr. Yongchun Yang is General Manager at Jiangsu Kanion Pharmaceutical Co. Ltd. since April 9, 2021 and has been its Director since December 27, 2019. Mr. Yang served as Chief Marketing Officer and Deputy G...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yongchun Yang	GM & Director	3.6yrs	CN¥758.60k	0.037% CN¥ 3.0m
Suocheng Jiang	Deputy Chief Accountant	1.8yrs	CN¥207.50k	0.0044% CN¥ 357.2k
Feipeng Xian	Deputy General Manager	1.4yrs	CN¥521.10k	0.0070% CN¥ 571.3k
Quan Liu	Deputy General Manager	4.9yrs	CN¥742.70k	0.025% CN¥ 2.0m
Yu Pan	Deputy GM & Market Development Center	2.7yrs	CN¥1.07m	0.025% CN¥ 2.0m
Yun Wu	Deputy General Manager	1.4yrs	CN¥637.00k	0.018% CN¥ 1.5m
Chuanlei Wang	Deputy General Manager	2.7yrs	CN¥710.40k	0.025% CN¥ 2.0m
Pan Peng	Secretary	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

47.5yo

평균 연령

경험이 풍부한 관리: 600557 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yongchun Yang	GM & Director	4.9yrs	CN¥758.60k	0.037% CN¥ 3.0m
Wei Xiao	Chairman	24yrs	CN¥2.39m	2.99% CN¥ 243.0m
Zhenzhong Wang	Vice Chairman of the Board	8.2yrs	CN¥1.03m	0.037% CN¥ 3.0m
Meiling Jiang	Supervisor	1.4yrs	데이터 없음	데이터 없음
Min Xu	Independent Director	3.5yrs	CN¥100.00k	데이터 없음
Kaixian Chen	Independent Director	4.9yrs	CN¥100.00k	데이터 없음
Wu Di	Supervisor	2.5yrs	데이터 없음	데이터 없음
Xuebin Chen	Director	1.4yrs	CN¥641.10k	0.0098% CN¥ 799.9k
Lin Jiang	Supervisor	1.4yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: 600557 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Jiangsu Kanion PharmaceuticalLtd 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Earnings quality

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) agreed to acquire Jiangsu Zhongxin Medicine Co.,Ltd. from Jiangsu Kanion Group Co Ltd and Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) for CNY 270 million.

Investor sentiment improves as stock rises 15%

Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Investor sentiment improves as stock rises 18%

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Full year 2023 earnings released: EPS: CN¥0.93 (vs CN¥0.75 in FY 2022)

Now 20% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in FY 2021)

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥9.43

New 90-day low: CN¥10.99

New 90-day low: CN¥12.14

Third quarter earnings released

New 90-day low: CN¥12.29

New 90-day low - CN¥12.67

New 90-day low - CN¥12.93

First half earnings released

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령